Horizon Discoveries, a biotech spin-out from Cambridge University, has announced the close of a £18.2m ($29.1m) series C round.
The round was led by Dr Jonathan Milner, chief executive of life science firm Abcam. New investors in Horizon include the University of Cambridge Enterprise Fund, investment fund Wren Capital and venture firm Calculus Capital. Joining in participation were DFJ Esprit, MVM Life Science, Roche Venture Fund, and Providence Investment Company.
Horizon, based in Cambridge’s tech cluster, has raised a total…
